These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 21969495)
1. Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. Bendell JC; Nemunaitis J; Vukelja SJ; Hagenstad C; Campos LT; Hermann RC; Sportelli P; Gardner L; Richards DA J Clin Oncol; 2011 Nov; 29(33):4394-400. PubMed ID: 21969495 [TBL] [Abstract][Full Text] [Related]
2. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965 [TBL] [Abstract][Full Text] [Related]
3. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. Díaz-Rubio E; Tabernero J; Gómez-España A; Massutí B; Sastre J; Chaves M; Abad A; Carrato A; Queralt B; Reina JJ; Maurel J; González-Flores E; Aparicio J; Rivera F; Losa F; Aranda E; J Clin Oncol; 2007 Sep; 25(27):4224-30. PubMed ID: 17548839 [TBL] [Abstract][Full Text] [Related]
4. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial. Yalcin S; Uslu R; Dane F; Yilmaz U; Zengin N; Buyukunal E; Buyukberber S; Camci C; Sencan O; Kilickap S; Ozdener F; Cevik D Oncology; 2013; 85(6):328-35. PubMed ID: 24247559 [TBL] [Abstract][Full Text] [Related]
5. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. Tebbutt NC; Wilson K; Gebski VJ; Cummins MM; Zannino D; van Hazel GA; Robinson B; Broad A; Ganju V; Ackland SP; Forgeson G; Cunningham D; Saunders MP; Stockler MR; Chua Y; Zalcberg JR; Simes RJ; Price TJ J Clin Oncol; 2010 Jul; 28(19):3191-8. PubMed ID: 20516443 [TBL] [Abstract][Full Text] [Related]
6. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. Baselga J; Segalla JG; Roché H; Del Giglio A; Pinczowski H; Ciruelos EM; Filho SC; Gómez P; Van Eyll B; Bermejo B; Llombart A; Garicochea B; Durán MÁ; Hoff PM; Espié M; de Moraes AA; Ribeiro RA; Mathias C; Gil Gil M; Ojeda B; Morales J; Kwon Ro S; Li S; Costa F J Clin Oncol; 2012 May; 30(13):1484-91. PubMed ID: 22412143 [TBL] [Abstract][Full Text] [Related]
7. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. Ohtsu A; Shah MA; Van Cutsem E; Rha SY; Sawaki A; Park SR; Lim HY; Yamada Y; Wu J; Langer B; Starnawski M; Kang YK J Clin Oncol; 2011 Oct; 29(30):3968-76. PubMed ID: 21844504 [TBL] [Abstract][Full Text] [Related]
8. Capecitabine: a review. Walko CM; Lindley C Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604 [TBL] [Abstract][Full Text] [Related]
9. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. Fuchs CS; Marshall J; Mitchell E; Wierzbicki R; Ganju V; Jeffery M; Schulz J; Richards D; Soufi-Mahjoubi R; Wang B; Barrueco J J Clin Oncol; 2007 Oct; 25(30):4779-86. PubMed ID: 17947725 [TBL] [Abstract][Full Text] [Related]
10. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. Porschen R; Arkenau HT; Kubicka S; Greil R; Seufferlein T; Freier W; Kretzschmar A; Graeven U; Grothey A; Hinke A; Schmiegel W; Schmoll HJ; J Clin Oncol; 2007 Sep; 25(27):4217-23. PubMed ID: 17548840 [TBL] [Abstract][Full Text] [Related]
11. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053 [TBL] [Abstract][Full Text] [Related]
12. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167 [TBL] [Abstract][Full Text] [Related]
13. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Lim DH; Park YS; Park BB; Ji SH; Lee J; Park KW; Kang JH; Lee SH; Park JO; Kim K; Kim WS; Jung CW; Im YH; Kang WK; Park K Cancer Chemother Pharmacol; 2005 Jul; 56(1):10-4. PubMed ID: 15782313 [TBL] [Abstract][Full Text] [Related]
14. Capecitabine and mitomycin-C in the therapy of pretreated patients with metastatic colorectal cancer: single center retrospective study with 36 patients. Vrdoljak E; Omrcen T; Boban M; Hrepic D J BUON; 2008; 13(4):513-8. PubMed ID: 19145672 [TBL] [Abstract][Full Text] [Related]
15. Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study. Waddell T; Gollins S; Soe W; Valle J; Allen J; Bentley D; Morris J; Lloyd A; Swindell R; Taylor MB; Saunders MP Cancer Chemother Pharmacol; 2011 May; 67(5):1111-7. PubMed ID: 20676676 [TBL] [Abstract][Full Text] [Related]
16. Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy. Clemons M; Joy AA; Abdulnabi R; Kotliar M; Lynch J; Jordaan JP; Iscoe N; Gelmon K Breast Cancer Res Treat; 2010 Nov; 124(1):177-86. PubMed ID: 20814815 [TBL] [Abstract][Full Text] [Related]
17. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. Cassidy J; Tabernero J; Twelves C; Brunet R; Butts C; Conroy T; Debraud F; Figer A; Grossmann J; Sawada N; Schöffski P; Sobrero A; Van Cutsem E; Díaz-Rubio E J Clin Oncol; 2004 Jun; 22(11):2084-91. PubMed ID: 15169795 [TBL] [Abstract][Full Text] [Related]
18. A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer. Wolff RA; Fuchs M; Di Bartolomeo M; Hossain AM; Stoffregen C; Nicol S; Heinemann V Cancer; 2012 Sep; 118(17):4132-8. PubMed ID: 22213153 [TBL] [Abstract][Full Text] [Related]
19. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644 [TBL] [Abstract][Full Text] [Related]
20. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]